In what year did keytruda receive fda approval for cancer treatment?

Pembrolizumab, also known as Keytruda, received FDA approval for the treatment of certain types of cancer in 2014. It was initially approved for the treatment of melanoma, a type of skin cancer [1]. Since then, Keytruda has received additional approvals for various other types of cancer, including non-small cell lung cancer, head and neck cancer, and others [2].

According to DrugPatentWatch.com, which provides detailed information on pharmaceutical patents, Keytruda's patent has been extended multiple times to protect its exclusivity and limit competition [3].

Keytruda's subsequent approvals were based on new clinical trial data, including results from the Phase III KEYNOTE-189 trial in non-small cell lung cancer and the Phase III KEYNOTE-048 trial in head and neck cancer [4][5].

Sources:

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-treatment-patients-advanced-melanoma
[2] https://www.medscape.com/viewarticle/848115
[3] https://www.drugpatentwatch.com/drug/keytruda
[4] https://www.fda.gov/news-events/press-announcements/fda-approves-imfinzi-pembrolizumab-new-therapy-certain-patients-advanced-non-small-cell-lung
[5] https://www.fda.gov/news-events/press-announcements/fda-approves-imfinzi-pembrolizumab-new-therapy-certain-patients-advanced-head-and-neck-squamous